Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 3 2Phase 1/2 2Phase 4 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1Dermatologic 1

Conditions

Vomiting 3Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Germ Cell and Embryonal 1Nausea 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × fosaprepitant × Clear all
NCT01874119 2018-06-07

HDIL2/Emend

St. Louis University

Phase 2 Terminated
13 enrolled 7 charts
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Vomiting

NCT00895245 2017-05-18

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

University of Washington

Phase 2 Terminated
6 enrolled 5 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nausea, Vomiting

NCT01736917 2016-05-25

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Hoosier Cancer Research Network

Phase 2 Completed
65 enrolled 14 charts
Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡